Merck’s Q3 2016 call highlighted a strong quarter driven primarily by new data and approvals for KEYTRUDA, notably in first-line lung cancer, which positions the product as a potential game-changer in oncology. Management's upbeat tone and raised guidance for the year suggest confidence in sustained momentum from these advancements. Besides oncology, Merck’s performance was bolstered by steady demand in other segments like vaccines, although some pressure from VYTORIN and ZETIA's patent expirations was acknowledged. Overall, the positive developments regarding KEYTRUDA are likely to drive short-term stock appreciation.

[1]